- Trials with a EudraCT protocol (51)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
51 result(s) found for: Median nerve.
Displaying page 2 of 3.
EudraCT Number: 2016-001656-22 | Sponsor Protocol Number: 1601 | Start Date*: 2016-11-17 | |||||||||||
Sponsor Name:Ziekenhuis Oost Limburg | |||||||||||||
Full Title: The utility of liposomal bupivacaine for anesthesia and analgesia in patients treated with collagenase for the release of Dupuytren’s contracture: A randomized controlled trial. | |||||||||||||
Medical condition: Introduction of collagenase clostridium histolyticum injection for the treatment of Dupuytren’s contractures. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-003971-19 | Sponsor Protocol Number: RP-01 | Start Date*: 2006-01-24 | |||||||||||
Sponsor Name:MEDA AB [...] | |||||||||||||
Full Title: Clinical study to evaluate the ability of MUSE to increase erectile function in post-radical prostatectomy patients - Randomised, controlled, open study with two parallel groups comparing MUSE 250... | |||||||||||||
Medical condition: Erectile Dysfunction | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: DE (Prematurely Ended) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-001431-20 | Sponsor Protocol Number: CHDR1417 | Start Date*: 2015-08-17 | |||||||||||
Sponsor Name:Centre for Human Drug Research | |||||||||||||
Full Title: A randomized, double blind, double-dummy placebo controlled, 3-way cross-over study to determine the test-retest reliability of, and the effect of oral retigabine and riluzole on, peripheral motor ... | |||||||||||||
Medical condition: Amytrophic Lateral Sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-002321-35 | Sponsor Protocol Number: E2007-G000-338 | Start Date*: 2017-05-08 | |||||||||||
Sponsor Name:Eisai Limited | |||||||||||||
Full Title: A Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial With an Open-Label Extension Phase of Perampanel as Adjunctive Treatment in Subjects at Least 2 years of Age With Inadequately Cont... | |||||||||||||
Medical condition: Seizures associated with Lennox-Gastaut Syndrome (LGS) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Prematurely Ended) BE (Prematurely Ended) LV (Prematurely Ended) PL (Prematurely Ended) CZ (Completed) FR (Prematurely Ended) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-023331-42 | Sponsor Protocol Number: IMIOXC | Start Date*: 2010-12-15 | |||||||||||
Sponsor Name:Department of Neurology, Odense University Hospital | |||||||||||||
Full Title: Oxcarbazepine for the treatment of chronic peripheral neuropathic pain: predictors of response - a randomised, double-blind, placebo-controlled clinical trial | |||||||||||||
Medical condition: Chronic peripheral neuropathic pain caused by polyneuropathy, postherpetic neuralgia and traumatic/surgical nerve injury. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-000388-15 | Sponsor Protocol Number: VesPa | Start Date*: 2016-08-31 |
Sponsor Name:University of the University of Munich | ||
Full Title: Prophylactic treatment of vestibular paroxysmia with carbamazepine: a prospective, randomized, placebo-controlled, cross-over, multi-center trial | ||
Medical condition: The main symptoms of vestibular paroxysmia are brief attacks of rotatory or postural vertigo lasting seconds to a few minutes with or without ear symptoms (tinnitus and hypoacusis). As in trigemina... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2020-001509-21 | Sponsor Protocol Number: B7981037 | Start Date*: 2020-12-08 | |||||||||||
Sponsor Name:Pfizer Inc. | |||||||||||||
Full Title: A PHASE 2a, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY INVESTIGATING THE SAFETY OF RITLECITINIB (PF 06651600) IN ADULT PARTICIPANTS WITH ALOPECIA AREATA | |||||||||||||
Medical condition: Alopecia areata | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-003034-16 | Sponsor Protocol Number: GEIS-74 | Start Date*: 2022-10-06 | |||||||||||
Sponsor Name:Grupo Español de Investigación en Sarcomas (GEIS) | |||||||||||||
Full Title: Phase I/II randomized trial of LB-100 plus doxorubicin vs. doxorubicin alone in first line of advanced soft tissue sarcomas | |||||||||||||
Medical condition: Advanced/metastatic soft tissue sarcoma (undifferentiated pleomorphic sarcoma, leiomyosarcoma, myxoid and hypercellular myxoid liposarcoma, myxofibrosarcoma, NOS sarcoma, synovial sarcoma, fibrosar... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-001186-20 | Sponsor Protocol Number: GEIS-83 | Start Date*: 2021-10-22 |
Sponsor Name:GRUPO ESPAÑOL DE INVESTIGACIÓN EN SARCOMAS | ||
Full Title: Phase Ib/II multicohort trial of different schemes of PM14 in monotherapy and in combination with radiotherapy in soft tissue sarcomas and other solid tumors | ||
Medical condition: Advanced soft tissue sarcoma and other solid tumors | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2016-003774-40 | Sponsor Protocol Number: TheStopGISTtrial | Start Date*: 2016-11-09 | |||||||||||
Sponsor Name:Oslo University Hospital | |||||||||||||
Full Title: Discontinuation of imatinib in patients with oligo-metastatic gastrointestinal stromal tumor that has become radiologically undetectable with treatment | |||||||||||||
Medical condition: Gastrointestinal stromal tumour (GIST) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NO (Prematurely Ended) FI (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-005557-73 | Sponsor Protocol Number: I10E-1302 | Start Date*: 2014-10-21 | |||||||||||
Sponsor Name:LFB BIOTECHNOLOGIES | |||||||||||||
Full Title: An international, multicentre, efficacy and safety study of I10E in initial and maintenance treatment of patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy | |||||||||||||
Medical condition: Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) ES (Completed) IT (Completed) FR (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-001768-60 | Sponsor Protocol Number: CNS 2007 04 | Start Date*: 2007-10-01 | |||||||||||
Sponsor Name:University of Birmingham | |||||||||||||
Full Title: A Phase II Multi-Centre Study of Concomitant and Prolonged Adjuvant Temozolomide with Radiotherapy in Diffuse Pontine Gliomas | |||||||||||||
Medical condition: Diffuse pontine glioma in children | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-002224-17 | Sponsor Protocol Number: 201805GON | Start Date*: 2019-05-07 |
Sponsor Name:Leids Universitair Medisch Centrum | ||
Full Title: GON-injection for a sooner and better treatment of cluster headache: a double-blind randomized controlled trial | ||
Medical condition: Episodic cluster headache | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2012-002465-35 | Sponsor Protocol Number: B3461028 | Start Date*: 2014-04-07 | |||||||||||
Sponsor Name:FoldRx Pharmaceuticals, a Pfizer Company | |||||||||||||
Full Title: A multicentre, international, phase 3, double-blind, placebo-controlled, randomized study to evaluate the efficacy, safety and tolerability of daily oral dosing of tafamidis meglumine (PF-06291826)... | |||||||||||||
Medical condition: Transthyretin amyloid cardiomyopathy (TTR-CM) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) IT (Completed) ES (Completed) DE (Completed) SE (Completed) CZ (Completed) NL (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-001337-41 | Sponsor Protocol Number: YKP3089C025 | Start Date*: 2018-12-17 | |||||||||||
Sponsor Name:SK Life Science, Inc. | |||||||||||||
Full Title: A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Cenobamate Adjunctive Therapy in Subjects with Primary Generalized Tonic-Clonic Seizures | |||||||||||||
Medical condition: Primary Generalized Tonic-Clonic Seizures | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Trial now transitioned) BG (Completed) CZ (Completed) SK (Trial now transitioned) PL (Trial now transitioned) DE (Trial now transitioned) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-003145-99 | Sponsor Protocol Number: CCMROne | Start Date*: 2015-03-19 | |||||||||||
Sponsor Name:Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge | |||||||||||||
Full Title: A randomised placebo-controlled study of the safety and tolerability of a retinoid-X receptor agonist's ability to promote remyelination in people with relapsing-remitting multiple sclerosis alread... | |||||||||||||
Medical condition: Relapsing-remitting multiple sclerosis already on interferon-beta therapy | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-001547-43 | Sponsor Protocol Number: ET19-075 | Start Date*: 2022-01-18 | |||||||||||
Sponsor Name:Centre Léon Bérard | |||||||||||||
Full Title: ATEZOGIST – A prospective, randomized, multicenter, comparative study of the efficacy of imatinib resumption combined with atezolizumab versus imatinib resumption alone in patients with unresectabl... | |||||||||||||
Medical condition: Unresectable locally advanced or metastatic gastrointestinal stromal tumors (GIST) after failure of standard treatments | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-003239-38 | Sponsor Protocol Number: PH-L19TNFDOX2-03/16 | Start Date*: 2017-07-28 | ||||||||||||||||
Sponsor Name:Philogen S.p.A. | ||||||||||||||||||
Full Title: A Phase III study comparing the efficacy of the combination of doxorubicin and the tumor-targeting human antibody-cytokine fusion protein L19TNF to doxorubicin alone as first-line therapy in patien... | ||||||||||||||||||
Medical condition: Unresectable or metastatic soft tissue sarcoma | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) IT (Trial now transitioned) FR (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-005558-31 | Sponsor Protocol Number: I10E-1306 | Start Date*: 2015-01-08 | |||||||||||
Sponsor Name:LFB BIOTECHNOLOGIES | |||||||||||||
Full Title: International, multicentre, efficacy and safety study of I10E in the maintenance treatment of patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy: Extension of PRISM study I1... | |||||||||||||
Medical condition: Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) ES (Completed) IT (Prematurely Ended) FR (Prematurely Ended) DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-005229-95 | Sponsor Protocol Number: PBKR03-001 | Start Date*: 2021-08-23 | |||||||||||
Sponsor Name:Passage Bio, Inc. | |||||||||||||
Full Title: A Phase 1/2 Open-Label, Multicenter, Dose Ranging and Confirmatory Study to Assess the Safety, Tolerability and Efficacy of PBKR03 Administered to Pediatric Subjects with Early Infantile Krabbe Dis... | |||||||||||||
Medical condition: Krabbe disease (globoid cell leukodystrophy) is an autosomal recessive lysosomal storage disease (LSD) caused by mutations in the gene encoding the hydrolytic enzyme galactosylceramidase (galactoce... | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
